Hansa Biopharma Management
Management criteria checks 1/4
Hansa Biopharma's CEO is Renee Aguiar-Lucander, appointed in Apr 2025, has a tenure of 1.42 years. total yearly compensation is SEK19.84M, comprised of 22.5% salary and 77.5% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $579.70K. The average tenure of the management team and the board of directors is 1.4 years and 1.6 years respectively.
Key information
Renee Aguiar-Lucander
Chief executive officer
SEK 19.8m
Total compensation
| CEO salary percentage | 22.47% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.4yrs |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -SEK 755m |
| Mar 31 2026 | n/a | n/a | -SEK 692m |
| Dec 31 2025 | SEK 20m | SEK 4m | -SEK 534m |
Compensation vs Market: Renee's total compensation ($USD2.03M) is about average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Insufficient data to compare Renee's compensation with company performance.
CEO
Renee Aguiar-Lucander (64 yo)
Mrs. Renée Aguiar-Lucander is Director of AC Immune SA since 2025. She is Independent Director of Inventiva S.A. from May 22, 2025. Mrs. Aguiar-Lucander has been Chief Executive Officer of Hansa Biopharma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.4yrs | SEK 19.84m | 0.15% $ 579.7k | |
| Chief Financial Officer | less than a year | no data | no data | |
| COO & President of U.S. | 1.3yrs | no data | no data | |
| Chief Scientific & Technology Officer | 2.8yrs | no data | no data | |
| Vice President of Finance & Administration | 7.3yrs | no data | no data | |
| VP & Head of Investor Relations | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 1.1yrs | no data | no data | |
| Chief Human Resources Officer | 1.1yrs | no data | no data | |
| VP & Head of Business Development | no data | no data | no data | |
| Head of Science | no data | no data | no data | |
| VP & Head of Medical Affairs | no data | no data | no data | |
| VP & Head of Research and Development | 5.4yrs | no data | no data |
Experienced Management: HNSB.F's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 7.3yrs | SEK 493.00k | 0.00098% $ 3.9k | |
| Independent Chairman of the Board | 4.3yrs | SEK 1.31m | 0.041% $ 160.4k | |
| Independent Director | 1yr | no data | no data | |
| Director | 1yr | SEK 205.00k | 0.025% $ 96.6k | |
| Chairman of European Medical Advisory Board in Transplantation | no data | no data | no data | |
| Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation | no data | no data | no data | |
| Member of European Medical Advisory Board in Transplantation | no data | no data | no data | |
| Chairman of US Medical Advisory Board in Transplantation | no data | no data | no data | |
| Member of US Medical Advisory Board in Transplantation | no data | no data | no data | |
| Director | 1yr | no data | no data | |
| Independent Director | 2.3yrs | SEK 526.00k | 0.36% $ 1.4m |
Experienced Board: HNSB.F's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/16 04:21 |
| End of Day Share Price | 2026/07/30 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hansa Biopharma AB (publ) is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Christian Lee | ABG Sundal Collier Sponsored |
| Madhu Kumar | B. Riley Securities, Inc. |